Justin Larkin
Bio + Health

Justin Larkin



More About Justin

Justin Larkin, MD, is an investing partner on the Bio + Health team, where he focuses on healthtech, spanning both verticalized care delivery and horizontal infrastructure approaches. He helped lead investments and is involved with a number of the Bio + Health portfolio companies including Akasa, Ambience, Bold, Devoted, Firefly Health, Levels, Omada, Marley Medical, Memora, Patina, Q Bio, Sprinter, Tomorrow Health, Waymark, and Zus.

Before joining a16z, Justin led the Strategy and Ops org at Verily (healthcare/life sciences arm of Alphabet), working across their care delivery, software analytics, and connected devices products. Prior to that, Justin was a cofounder and product/clinical lead at Wellsheet, a healthtech company focused on using ML to enable digital workflows for physicians.

Justin holds an MD from the University of Pennsylvania, where he was a founding member of PennHealthX, an endowed program for cross-disciplinary training in clinical medicine and health technology/entrepreneurship. Justin also holds an MBA from the Stanford Graduate School of Business, as well as a BS/BA from BYU in developmental biology and Portuguese, respectively. When not obsessing over the future of healthtech, Justin can usually be found playing zone defense against his three little kids, chasing backcountry snow, or exploring the California coast.

Latest Content

  • CMO vs. CPO with Peter Shalek and Reena Pande
    Justin Larkin, Reena Pande, Peter Shalek, Julie Yoo, Kris Tatiossian, and Olivia Webb

    As Julie mentions during the episode, there’s international relations, and then there’s CMO/CPO relations. Peter and Reena talk about working together to improve their relationship and the outcomes of their teams, and they get granular about what worked and what didn’t.

  • Investing in Hippocratic AI
    Julie Yoo and Justin Larkin

    The very nature of generative AI—conversational, scalable, accessible to non-technical users—has the potential to solve the shortcomings of previous generations of rules-based chatbots and other such products in making these concepts a reality.

  • Investing in Marker Learning
    Annie Collins, Justin Larkin, Anne Lee Skates, Daisy Wolf, and Julie Yoo

    Every student can learn, just not on the same day, or the same way. – George Evans

  • Risk-based Contracting for Value-based Care
    Justin Larkin and Julie Yoo

    COVID has strained our healthcare system, payors are feeling the squeeze of rising costs, and patients are bearing the brunt of the current system’s shortcomings. As a result, healthcare is undergoing a transformat...

  • New Year, New Fund, New Opportunities in Bio + Health
    Vineeta Agarwala, Jorge Conde, Justin Larkin, Vijay Pande, Becky Pferdehirt, Jay Rughani, Judy Savitskaya, Daisy Wolf, and Julie Yoo

    2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both...

Load More
go to top